Advances in hepatoblastoma treatment have improved survival but have been accompanied
by the chronic toxicities of pediatric cancer therapy. Cisplatin is the cornerstone
of chemotherapy treatment for hepatoblastoma. The most frequent long-term complication
of hepatoblastoma treatment is cisplatin-related ototoxicity. Among children who receive
cisplatin, 25-90% will exhibit measurable hearing loss, impacting language and social
development [
[1]
]. Therefore, efforts to identify children eligible for reduction or elimination of
cisplatin-based chemotherapy while maintaining excellent oncologic outcomes are paramount
in reducing the long-term toxicities of hepatoblastoma cancer treatment.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Pediatric SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.Cancer. 2009; 115: 5623-5626
- Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: report from Children's Oncology Group Trial, AHEP0731.Journal of Pediatric Surgery. 2022;
- Surgical Management of Hepatoblastoma and Recent Advances.Cancers (Basel). 2019; 11
- Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children's Oncology Group.J Clin Oncol. 2011; 29: 3301-3306
- 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT).Pediatr Radiol. 2018; 48: 536-554
- Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.Lancet Oncol. 2019; 20: 719-727
Article info
Publication history
Published online: June 16, 2022
Accepted:
June 13,
2022
Received:
June 10,
2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
